Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Pricing Debate Medicare Executive Changes

The Best Choice: HHS Lead On Drug Price Reform Brings Expertise In Part D Contracting

  • Analysis

Executive Summary

Appointment of CVS Health executive Daniel Best could help Centers for Medicare and Medicaid Services address some pharmacy benefit manager concerns with point-of-sale rebates in Part D.

You may also be interested in...



US Reimbursement Briefs: Medicare Payments For New Drugs; 340B Rules; HHS' Best

Recent developments in US federal government regulation of prescription drug pricing and reimbursement.

Trump's Drug Pricing Plans On Slow Walk? HHS To Solicit Comment On Policies

No big policy implementation expected to be announced during president's speech planned for next week. HHS will continue to gather feedback on various approaches to lowering drug pricing.

UnitedHealthcare Will Share The Savings: Point-Of-Sale Rebates Coming In 2019

Biggest benefit to manufacturers from the insurer's upcoming program may be relieving public pressure on list prices.

Table

View full table

Related Content

Pink Sheet

Topics

Related Companies

Tags:
Pricing Debate Medicare Executive Changes
Latest Headlines

Xtandi Still Faces Likely US Price Cut Even As It Avoids ‘March In’ Proceeding

Moderna CEO Reminds People About Value Of Government Negotiations At Senate Hearing

Accelerated Approval: Potential Sources Of Confirmatory Evidence Weighed At Tofersen Review

PBM Transparency Act Advances In Senate And It’s A Far Cry From The Rebate Rule

See All
UsernamePublicRestriction

Register

PS122820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By